NCT00150254已完成2 期
A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 625
- 试验地点
- 12
- 主要终点
- 4 week continuous quit rate (CQR) at Weeks 9-12 and Weeks 4-7
研究概览
简要总结
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have smoked on average of at least ten cigarettes per day during the past year
- •Subjects must have no period of abstinence greater than three months in the past year
排除标准
- •Subjects with any history of clinically significant cardiovascular disease
- •Uncontrolled hypertension
结局指标
主要结局
4 week continuous quit rate (CQR) at Weeks 9-12 and Weeks 4-7
次要结局
- Number of cigarettes smoked per day
- Continuous abstinence rate from target quit date to end of treatment (Week 12)
- Carbon monoxide(CO)-confirmed 7-day point prevalence of abstinence at Week 12
- Urge to smoke and withdrawal symptoms assessed by Minnesota Nicotine Withdrawal Scale
- Rewarding effects of smoking assessed by Smoking Effects Inventory
- Weight change from baselin
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary FibrosisPulmonary FibrosisNCT00514683Boehringer Ingelheim432
终止
2 期
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic DermatitisAtopic DermatitisNCT00455429Johnson & Johnson Pharmaceutical Research & Development, L.L.C.84
已完成
2 期
Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPDChronic Obstructive Pulmonary Disease (COPD)NCT02680197Chiesi Farmaceutici S.p.A.262
已完成
2 期
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid ArthritisArthritis, RheumatoidNCT00550446Pfizer386
已完成
2 期
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma MedicationsAsthmaNCT01576718Teva Branded Pharmaceutical Products R&D, Inc.889